| Drug General Information |
| Drug ID |
D0XL7C
|
| Former ID |
DNC005020
|
| Drug Name |
4-Pyridin-2-yl-5-quinolin-4-yl-thiazol-2-ylamine
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C17H12N4S
|
| Canonical SMILES |
C1=CC=C2C(=C1)C(=CC=N2)C3=C(N=C(S3)N)C4=CC=CC=N4
|
| InChI |
1S/C17H12N4S/c18-17-21-15(14-7-3-4-9-19-14)16(22-17)12-8-10-20-13-6-2-1-5-11(12)13/h1-10H,(H2,18,21)
|
| InChIKey |
UPYLCJSMNYCTLZ-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
TGF-beta receptor type I |
Target Info |
Inhibitor |
[1]
|
|---|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
Cytokine-cytokine receptor interaction
|
|
FoxO signaling pathway
|
|
Endocytosis
|
|
TGF-beta signaling pathway
|
|
Osteoclast differentiation
|
|
Hippo signaling pathway
|
|
Adherens junction
|
|
Chagas disease (American trypanosomiasis)
|
|
Hepatitis B
|
|
HTLV-I infection
|
|
Pathways in cancer
|
|
Colorectal cancer
|
|
Pancreatic cancer
|
|
Chronic myeloid leukemia
|
|
PANTHER Pathway
|
TGF-beta signaling pathway
|
|
Pathway Interaction Database
|
Glypican 1 network
|
|
ALK1 signaling events
|
|
Beta5 beta6 beta7 and beta8 integrin cell surface interactions
|
|
TGF-beta receptor signaling
|
|
Reactome
|
TGF-beta receptor signaling activates SMADs
|
|
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
|
|
SMAD2/3 Phosphorylation Motif Mutants in Cancer
|
|
SMAD2/3 MH2 Domain Mutants in Cancer
|
|
TGFBR2 Kinase Domain Mutants in Cancer
|
|
TGFBR1 KD Mutants in Cancer
|
|
TGFBR1 LBD Mutants in Cancer
|
|
WikiPathways
|
TGF Beta Signaling Pathway
|
|
p38 MAPK Signaling Pathway
|
|
MAPK Signaling Pathway
|
|
TGF beta Signaling Pathway
|
|
Extracellular vesicle-mediated signaling in recipient cells
|
|
Cardiac Hypertrophic Response
|
|
Signaling by TGF-beta Receptor Complex
|
|
Integrated Pancreatic Cancer Pathway
|
|
Integrated Breast Cancer Pathway
|
| References |
| REF 1 | J Med Chem. 2004 Aug 26;47(18):4494-506.Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors. |
|---|
